The Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program

Overview

The Pre-DICTED (Pre-Diabetes Intervention and Continued Tracking to Ease-out Diabetes) program is a community-based diabetes prevention program. This study aims to test the effectiveness of structured, group-based lifestyle interventions with stepwise addition of metformin, if required, among subjects with pre-diabetes in multi-ethnic Singapore.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 30, 2024

Detailed Description

The Pre-DICTED program is designed as a randomized, controlled, pragmatic trial. The program targets to recruit up to 846 overweight/obese (BMI ≥23.0) adults (age 18-64) with isolated impaired fasting glucose (IFG), isolated impaired glucose tolerance (IGT), or IFG + IGT in Singapore. The follow-up period will be 3 years. Eligible subjects will be identified through community, primary care clinics and hospital-based diabetes screening program. Following informed consent, eligible participants will be randomised into the control or the treatment arm. Participants in the control arm will receive the current standard of care for pre-diabetes which includes counseling on lifestyle modifications and follow up by primary care physicians. Participants in the treatment arm will undergo a 3-month, locally tailored, group-based lifestyle intervention program (consisting of nutrition workshops, exercise sessions and goal-setting workshop) plus subsequent stepwise addition of metformin for selected participants at the highest risk of progression to diabetes at ≥ 6 months of follow-up. Financial incentives will be awarded to participants who achieve weight lost of ≥5% of baseline weight during follow-up period. The primary outcome of diabetes incidence will be assessed bi-annually and compared across the study arms. Secondary outcomes will include weight, waist circumference, fasting plasma glucose (FPG), 2-h glucose, HbA1c, physical activity, diet and metformin adherence.

Interventions

  • Behavioral: Lifestyle modification
    • Participants in the treatment arm will receive structured, locally tailored, group-based lifestyle interventions that consist of a core intervention phase (3 months) and a maintenance phase (33 months). The core intervention phase will consist of twice weekly group sessions on nutrition, exercise and goal-setting within the first 6 weeks followed by 6 weeks of self-directed lifestyle modification. During the maintenance phase, the participants will receive monthly short message service (SMS) on health tips as well as 6 monthly telephone calls from program coordinators.
  • Drug: Metformin
    • Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.
  • Other: Financial incentives
    • Participants will be given cash incentives if they meet the weight loss target, which is pre-defined as 5% of baseline weight, at the 3rd, 6th, 12th, 18th, 24th, 30th and 36th month of study period.

Arms, Groups and Cohorts

  • Experimental: Treatment arm
    • Participants in the treatment arm will receive structured group-based lifestyle interventions with stepwise addition of metformin for selected high-risk participants.
  • No Intervention: Control
    • Participants in the control arm will receive the current standard of care for pre-diabetes which includes counseling on lifestyle modifications and follow up by primary care physicians.

Clinical Trial Outcome Measures

Primary Measures

  • Diabetes incidence
    • Time Frame: 3 years
    • The primary outcome, diabetes incidence, will be diagnosed based on a single, annual OGTT or the semi-annual FPG (Fasting plasma glucose) test

Secondary Measures

  • Weight
    • Time Frame: 3 years
    • Weight in kg
  • Waist circumference
    • Time Frame: 3 years
    • Waist circumference in cm
  • HbA1c
    • Time Frame: 3 years
    • HbA1c in %
  • Fasting plasma glucose
    • Time Frame: 3 years
    • Fasting plasma glucose in mmol/L
  • 2-hour plasma glucose
    • Time Frame: 3 years
    • 2-hour plasma glucose post oral glucose challenge in mmol/L
  • International physical activity questionnaire (IPAQ) score
    • Time Frame: 3 years
    • IPAQ score in MET minutes a week
  • Metformin adherence
    • Time Frame: Up to 30 months
    • Metformin adherence assessed by pill counts

Participating in This Clinical Trial

Inclusion Criteria

1. Singapore citizens or permanent residents 2. Age between 18 and 64 3. Body mass index (BMI) ≥ 23.0 kg/m2 4. Pre-diabetes diagnosed based on: 1. fasting plasma glucose 6.1 – 6.9 mmol/L (Impaired fasting glucose; IFG) and/or 2. 2-hr plasma glucose in 75g oral glucose tolerance test (OGTT) 7.8 – 11.0 mmol/L (Impaired glucose tolerance; IGT) (Laboratory tests to be done within 6 months of enrolment) Exclusion Criteria:

1. Individuals with diabetes mellitus 2. Health conditions impeding participation in lifestyle change programme (e.g. active cancer, recent myocardial event within 6 months, heart failure, chronic kidney disease) 3. Current pregnancy or breast feeding 4. Treatment with medications known to alter glucose tolerance 5. Known allergic reaction to metformin

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 64 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Singapore General Hospital
  • Collaborator
    • Ministry of Health, Singapore
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Yong Mong Bee, Principal Investigator, Singapore General Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.